Latest Vorinostat Stories
Pivotal Phase 3 Clinical Trial Targeted to Begin in First Half of 2015 PRINCETON, N.J., Sept. 17, 2014 /PRNewswire/ -- Soligenix, Inc.
A new mouse study suggests that a class of drugs approved to treat leukemia and epilepsy also may be effective against kidney stones, researchers at Washington University School of Medicine in St. Louis report.
Transparency Market Research has added a new report titled "Histone Deacetylase Inhibitors Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019" to
The global market for histone deacetylase inhibitors (HDIs) was valued at $223.2 million in 2012 and was estimated at $361.8 million for 2013.
A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments.
A team of researchers at the University of North Carolina at Chapel Hill have successfully flushed latent HIV infection from hiding, with a drug used to treat certain types of lymphoma.
Adding a drug that activates genes to frontline combination therapy for acute myeloid leukemia resulted in an 85 percent remission rate after initial treatment, researchers at The University of Texas MD Anderson Cancer Center reported at the 53rd Annual Meeting of the American Society of Hematology.
WALTHAM, Mass., March 31, 2011 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., a clinical-stage epigenetics oncology company, today announced 11 posters on entinostat, an oral, highly selective, class I histone deacetylase (HDAC) inhibitor, will be presented at the 102nd Annual American Association for Cancer Research meeting April 2 to April 6 in Orlando, FL.
- The governor of a province or people.